- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MOLECURE Aktie jetzt für 0€ handeln | |||||
| 28.03. | Strategic update on the progress and development of Molecure's key clinical projects in 2024 | 205 | GlobeNewswire (Europe) | Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02.... ► Artikel lesen | |
| 15.10.24 | Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. | 311 | GlobeNewswire (Europe) | This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as... ► Artikel lesen |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CO.DON | 0,016 | -27,27 % | CO.DON GmbH ist Partner des EU-geförderten Projekts zur Weiterentwicklung des 3D-Bioprinting für die Geweberegeneration | Teltow (ots) - Das im Dezember 2024 gestartete EU-geförderte Projekt micro2MACRO (m2M) zielt darauf ab, die Geweberegeneration durch eine innovative Bioprinting-Plattform voranzutreiben. m2M konzentriert... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,473 | -0,80 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| IMMATICS | 5,600 | -4,36 % | Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing... ► Artikel lesen | |
| ALDEYRA | 4,402 | -0,54 % | Hagens Berman Sobol Shapiro LLP: Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman | SAN FRANCISCO, April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over... ► Artikel lesen | |
| MEDIFAST | 12,340 | +0,73 % | MEDIFAST INC - 8-K, Current Report | ||
| PHARMING | 0,960 | +11,63 % | Pharming Group N.V.: Pharming Group reports second quarter and first half 2025 financial results and provides business update | Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased... ► Artikel lesen | |
| COHERUS ONCOLOGY | 0,861 | +1,20 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 12,200 | +0,83 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September | IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further details on EVERLAST-A study design to... ► Artikel lesen | |
| DBV TECHNOLOGIES | 1,690 | -3,76 % | DBV Technologies S.A.: DBV Technologies announces filing of 2025 Half-Year Report - Conditions for accessing or consulting the Report | Châtillon, France, July 29, 2025
DBV Technologies announces filing of 2025 Half-Year Report - Conditions for accessing or consulting the Report
DBV Technologies (Euronext: DBV - ISIN: FR0010417345... ► Artikel lesen | |
| INNOVIVA | 16,100 | -0,62 % | Innoviva Specialty Therapeutics, Inc.: FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 | FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new... ► Artikel lesen | |
| ARMATA PHARMACEUTICALS | 2,060 | 0,00 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia | All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met
AP-SA02 arm significantly improved clinical outcomes... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 1,050 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.07.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.07.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.07.2025ISIN NameCA78132X1042 RUGBY... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,600 | -1,05 % | SIGA Technologies Inc.: SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results | ||
| LIQUIDIA | 16,010 | -4,30 % | XFRA LT4: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 8,800 | +0,57 % | Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July... ► Artikel lesen |
MOLECURE SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +4,75 % bei einem Aktienkurs von 2,005 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.